newsfilter
← Latest News
GlobeNewswire·

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b